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Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans: 
Lost in translation 
 
We greatly appreciate the comments offered by Drs Rolle, Takematsu, and Hoffman 
and the opportunity to put our work into a wider perspective. We share the view that our work 
does not reflect the clinical situation but rather provides a proof of mechanism study, which 
aims to help to translate preclinical findings (Sprague et al., 2005) into the clinic.  
As we noted in the discussion of our work (Hysek et al., 2012b) the primary goal of the 
study was to investigate the role of adrenoceptors in the mechanism of action of MDMA in 
humans. Therefore, the study provided only indirect support for the use of carvedilol in the 
treatment of stimulant toxicity in which carvedilol would be administered following the 
ingestion of Ecstasy or other stimulants. Furthermore, we noted the limitation that the 
MDMA-induced increase in body temperature in our study was moderate and we do not 
know whether carvedilol would also be effective in cases of severe hyperthermia following 
ecstasy use.  
The dose MDMA of 125 mg used in our controlled experimental study represents a 
commonly used recreational dose of MDMA. Rolle et al. cited findings from a naturalistic 
observational study in experienced ecstasy users in a party setting in Australia (Morefield et 
al., 2011). Of 49 partying subjects, 34 subjects used doses of MDMA of 0-150 mg and 15 
users took cumulative doses of 150-280 mg (Morefield et al., 2011). The maximal total dose 
of MDMA was 280 mg. Most pills contained less than 100 mg of MDMA. A much larger study 
in 5,786 recreational drug users who handed in their tablets for analysis found that the 
average MDMA content in the ecstasy pills was 82.5 ± 35.2 mg (Brunt et al., 2012). Subjects 
presenting to emergency departments with any type of medical problems related to ecstasy 
use ingested less than two pills in 80% of the cases (Liechti et al., 2005; Williams et al., 
1998). Importantly, desirable effects of MDMA were reported to show an inverse U-shaped 
dose-effect curve with doses of 60-140 mg of MDMA producing maximal desirable effects 
(Brunt et al., 2012). In contrast, doses larger than 140 mg produced less desirable and more 
adverse effects (Brunt et al., 2012). Thus, users have an interest in taking total doses in the 
range of 60-140 mg. Clinical trials in patients with posttraumatic stress disorder used doses 
of MDMA of 125 mg supplemented by 62.5 mg (Mithoefer et al., 2010; Oehen et al., 2013).  
Severe hyperthermia is rare but it represents the most important complication of 
recreational MDMA use because of high mortality (Docherty et al., 2010; Henry et al., 1992; 
Parrott, 2012; Liechti et al., 2005; Rogers et al., 2009). The risk for MDMA-induced 
hyperthermic complications increases with repeated or high doses of MDMA (Parrott, 2012; 
Schutte et al., 2013), high ambient temperature (Dafters, 1995; Docherty et al., 2010), 
crowded conditions, physical exertion (Dafters, 1995), reduced fluid intake (Dafters, 1995), 
and hyperthyroidism (Martin et al., 2007; Sprague et al., 2007). One or several of these 
permissive factors are typically present in animal studies of MDMA-induced hyperthermia 
(Dafters, 1995; Schutte et al., 2013) and these risk factors should also be a concern in some 
recreational settings where MDMA and other amphetamines are consumed. For safety 
reasons these conditions are all avoided in controlled clinical studies. In controlled settings, 
MDMA produces only a small but well-documented increase in body temperature even in the 
absence of any known permissive factors (Hysek et al., 2012a; Hysek et al., 2012c; Liechti et 
al., 2001; Parrott, 2012).  
Treatment of hyperthermia should primarily include hydration, sedation with 
benzodiazepines, and cooling. Dantrolene has been used in patients with extreme 
hyperthermia (Grunau et al., 2010). However, the use of dantrolene in sympathomimetic 
drug-induced hyperthermia is controversial (Rusyniak et al., 2004). MDMA-induced 
hyperthermia is not associated with a genetic disposition for malignant hyperthermia (Schutte 
et al., 2013) and it should not be misclassified as malignant hyperthermia. Other less 
promising candidate treatments of ecstasy-intoxicated patients have been discussed 
(Rietjens et al., 2012).  
The mechanism of MDMA-induced thermogenesis involves serotonin (Docherty et al., 
2010) as well as noradrenaline, α1 and β3 adrenoceptors, and mitochondrial uncoupling 
proteins (Mills et al., 2003; Sprague et al., 2005; Sprague et al., 2007). Carvedilol blocked 
the effects of noradrenaline and not only significantly decreased the thermogenic effects of 
MDMA in humans but also reversed established MDMA-induced hyperthermia in rats when 
carvedilol was administered after MDMA (Sprague et al., 2005). Importantly, α-β-blockers 
also effectively reduce the cardiostimulant effects of psychostimulants. It is critical to block 
both α and β adrenoceptors to reduce increases in both blood pressure and heart rate 
(Boehrer et al., 1993; Hysek et al., 2012b). Blocking only α1 adrenoceptors lowered blood 
pressure and body temperature but enhanced heart rate increases in response to MDMA 
(Hysek et al., 2013). In contrast, blocking only β adrenoceptors lowered tachycardia but 
enhanced the pressure response to cocaine (Ramoska et al., 1985) or MDMA (Hysek et al., 
2010).  
We agree with Rolle and colleagues that the true utility of carvedilol in the treatment of 
significant MDMA toxicity is unknown. We would therefore suggest that the benefit of 
carvedilol or other α-β-blockers such as labetalol in patients presenting with drug-induced 
hyperthermia should further be evaluated. Because hyperthermic complications associated 
with psychostimulants are rare events, this can most likely only be done in single cases or 
case series and in the emergency medicine and critical care setting.  
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